As of April 15, 2025, Viatris (VTRS) has a market cap of $8.93 billion USD. According to our data, Viatris is ranked No.1755 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 15, 2025 | $8.93 B |
-39.91%
|
Dec 31, 2024 | $14.86 B |
19.68%
|
Dec 29, 2023 | $12.42 B |
2.06%
|
Dec 30, 2022 | $12.17 B |
-14.29%
|
Dec 31, 2021 | $14.19 B |
-26.12%
|
Dec 31, 2020 | $19.21 B |
-6.77%
|
Dec 31, 2019 | $20.61 B |
-26.64%
|
Dec 31, 2018 | $28.09 B |
-35.24%
|
Dec 29, 2017 | $43.38 B |
10.90%
|
Dec 30, 2016 | $39.11 B |
-29.44%
|
Dec 31, 2015 | $55.43 B |
-4.08%
|
Dec 31, 2014 | $57.79 B |
29.88%
|
Dec 31, 2013 | $44.49 B |
58.11%
|
Dec 31, 2012 | $28.14 B |
27.91%
|
Dec 30, 2011 | $22.00 B |
1.56%
|
Dec 31, 2010 | $21.66 B |
14.65%
|
Dec 31, 2009 | $18.89 B |
86.35%
|
Dec 31, 2008 | $10.14 B |
-29.66%
|
Dec 31, 2007 | $14.41 B |
-29.13%
|
Dec 29, 2006 | $20.34 B |
1.15%
|
Dec 30, 2005 | $20.11 B |
14.17%
|
Dec 31, 2004 | $17.61 B |
-29.58%
|
Dec 31, 2003 | $25.01 B |
63.53%
|
Dec 31, 2002 | $15.29 B |
-6.43%
|
Dec 31, 2001 | $16.35 B |
49.71%
|
Dec 29, 2000 | $10.92 B |
0.69%
|
Dec 31, 1999 | $10.84 B |
-19.48%
|
Dec 31, 1998 | $13.47 B |
51.31%
|
Dec 31, 1997 | $8.90 B |
27.08%
|
Dec 31, 1996 | $7.00 B |
-28.62%
|
Dec 29, 1995 | $9.81 B |
31.44%
|
Dec 30, 1994 | $7.47 B |
7.29%
|
Dec 31, 1993 | $6.96 B |
-19.02%
|
Dec 31, 1992 | $8.59 B |
52.08%
|
Dec 31, 1991 | $5.65 B |
103.20%
|
Dec 31, 1990 | $2.78 B |
-14.32%
|
Dec 29, 1989 | $3.25 B |
175.12%
|
Dec 30, 1988 | $1.18 B |
8.30%
|
Dec 31, 1987 | $1.09 B |
-25.19%
|
Dec 31, 1986 | $1.46 B |
-39.18%
|
Dec 31, 1985 | $2.39 B |
-27.59%
|
Dec 31, 1984 | $3.31 B |
27.67%
|
Dec 30, 1983 | $2.59 B |
10.42%
|
Dec 31, 1982 | $2.34 B |
6.67%
|
Dec 31, 1981 | $2.20 B |
107.69%
|
Dec 31, 1980 | $1.06 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Pfizer
PFE
|
$127.27 B |
-0.003 M
|
![]() USA
|
![]() Merck
MRK
|
$197.26 B |
0.003 M
|
![]() USA
|
![]() Johnson & Johnson
JNJ
|
$370.20 B |
0.003 M
|
![]() USA
|
![]() Bristol-Myers Squibb
BMY
|
$101.74 B |
-0.001 M
|
![]() USA
|
![]() Eli Lilly
LLY
|
$679.94 B |
-0.022 M
|
![]() USA
|
![]() AbbVie
ABBV
|
$312.76 B |
-0.013 M
|
![]() USA
|
![]() Amgen
AMGN
|
$158.77 B |
0.132 B
|
![]() USA
|
![]() Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
![]() USA
|
![]() Sanofi
SNY
|
$123.58 B |
-0.002 M
|
![]() France
|
![]() GlaxoSmithKline
GSK
|
$72.33 B |
-0.002 M
|
![]() UK
|
![]() AstraZeneca
AZN
|
$210.42 B |
-0.005 M
|
![]() UK
|
![]() Novartis
NVS
|
$217.12 B |
0.003 M
|
![]() Switzerland
|
![]() Teva Pharmaceutical Industries
TEVA
|
$15.60 B |
0.000 M
|
![]() Israel
|
Market Cap | = | VTRS Stock Price | * | VTRS Shares Outstanding |
= | $7.48 | * | 1.19 B | |
= | $8.93 B |